Volume 14, Issue 4 (11-2022)                   IJDO 2022, 14(4): 231-239 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Kumar Gupta P, Munivenkatappa Byregowda S, Munivenkatarayappa A, Hanumegowda R, Chithananthan C, S Daptardar S, et al . A Review of the Diabetic Status in India. IJDO 2022; 14 (4) :231-239
URL: http://ijdo.ssu.ac.ir/article-1-749-en.html
Assistant Professor, Department of Biotechnology, R.V College of Engineering, Bangalore-560059, India.
Abstract:   (1244 Views)
Objective: Diabetes mellitus (DM) also known as diabetes, is a chronic metabolic disorder that is rapidly becoming a worldwide concern with severe economic, social, and health consequences. Diabetes is a collection of metabolic illnesses defined by hyperglycemia that results due to abnormalities in the secretion of insulin, its action, or a combination of the two. According to the International Diabetes Federation (IDF), there were around 387 million diabetics worldwide in 2014, with that number anticipated to climb to 592 million by 2035.
Additionally, the fact that over half of the population has diabetes that goes undiagnosed adds to the difficulty of diagnosis. Diabetes is already on the increase in India as a result of a combination of genetic predisposition and lifestyle changes brought about by globalization and urbanization. Even though diabetes affects a large section of India's population, diabetes awareness campaigns are few and far between, although it is one of the most severe issues to be addressed. Regular exercise, stress management, yoga, and regular exercise, as well as mindful nutrition, are all important aspects of diabetes control. This research gives an overview of the current status of diabetes in India, as well as the influence of nutrition, geographic distribution, and air pollution on the spread of the disease. It also addresses some of the diabetic therapies.
 
Full-Text [PDF 213 kb]   (370 Downloads)    
Type of Study: Research | Subject: Special
Received: 2022/08/1 | Accepted: 2022/10/8 | Published: 2022/11/19

References
1. Sami W, Ansari T, Butt NS, Ab Hamid MR. Effect of diet on type 2 diabetes mellitus: A review. International journal of health sciences. 2017;11(2):65.
2. History of Diabetes Mellitus. https://www.researchgate.net/publication/336666069_History_of_Diabetes_Mellitus
3. Pathophysiology of diabetes: An overview. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791288/#__ffn_sectitle
4. Nagarathna R, Bali P, Anand A, Srivastava V, Patil S, Sharma G, et al. Prevalence of diabetes and its determinants in the young adults indian population-call for yoga intervention. Frontiers in endocrinology. 2020;11:507064. [DOI:10.3389/fendo.2020.507064]
5. Samanta S. Glycated hemoglobin and subsequent risk of microvascular and macrovascular complications. Indian Journal of Medical Sciences. 2021;73(2):230-8. [DOI:10.25259/IJMS_16_2020]
6. Khan MA, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes-global burden of disease and forecasted trends. Journal of epidemiology and global health. 2020;10(1):107. [DOI:10.2991/jegh.k.191028.001]
7. Maturity Onset Diabetes in the Young. https://www.ncbi.nlm.nih.gov/books/NBK532900/
8. Zhang H, Colclough K, Gloyn AL, Pollin TI. Monogenic diabetes: a gateway to precision medicine in diabetes. The Journal of Clinical Investigation. 2021;131(3). [DOI:10.1172/JCI142244]
9. Ch'ng JH, Moll K, Wyss K, Hammar U, Rydén M, Kämpe O, et al. Enhanced virulence of Plasmodium falciparum in blood of diabetic patients. Plos one. 2021;16(6):e0249666. [DOI:10.1371/journal.pone.0249666]
10. Gan D. Diabetes atlas. International Diabetes Federation; 2003.
11. Dieny FF, Tsani AF, Suryawati S. Visceral Adiposity Index and Lipid Accumulation Product Related to Insulin Resistance and Metabolic Syndrome in Obese College Students. Open Access Macedonian Journal of Medical Sciences. 2022;10(E):667-73. [DOI:10.3889/oamjms.2022.8880]
12. Doulamis IP, Tzani A, Konstantopoulos P, Daskalopoulou A, Spinos T, Bletsa E, et al. Experimental hypogonadism: insulin resistance, biochemical changes and effect of testosterone substitution. Journal of basic and clinical physiology and pharmacology. 2019;30(3). [DOI:10.1515/jbcpp-2018-0118]
13. Yasmin I, Khan WA, Naz S, Iqbal MW, Awuchi CG, Egbuna C, et al. Etiology of obesity, cancer, and diabetes. InDietary Phytochemicals. Springer, Cham. 2021:1-27. [DOI:10.1007/978-3-030-72999-8_1]
14. Griffin TP, O'Loughlin A, Dinneen SF. How Should Secondary Causes of Diabetes Be Excluded?. Clinical Dilemmas in Diabetes. 2021:45-67. [DOI:10.1002/9781119603207.ch4]
15. Tatachar A, Gibson CM. Sex hormones, related compounds and hormonal contraceptives including miscellaneous hormones. InSide Effects of Drugs Annual . Elsevier.2019;41:471-480. [DOI:10.1016/bs.seda.2019.06.003]
16. Yuan S, Giovannucci EL, Larsson SC. Gallstone disease, diabetes, calcium, triglycerides, smoking and alcohol consumption and pancreatitis risk: Mendelian randomization study. NPJ genomic medicine. 2021;6(1):1-7. [DOI:10.1038/s41525-021-00189-6]
17. Sandovici I, Fernandez-Twinn DS, Hufnagel A, Constância M, Ozanne SE. Sex differences in the intergenerational inheritance of metabolic traits. Nature Metabolism. 2022 30:1-7. [DOI:10.1038/s42255-022-00570-4]
18. Lin WY, Liu YL, Yang AC, Tsai SJ, Kuo PH. Active cigarette smoking is associated with an exacerbation of genetic susceptibility to diabetes. Diabetes. 2020;69(12):2819-29. [DOI:10.2337/db20-0156]
19. Sherigar JM, De Castro J, Yin YM, Guss D, Mohanty SR. Glycogenic hepatopathy: a narrative review. World journal of hepatology. 2018;10(2):172. [DOI:10.4254/wjh.v10.i2.172]
20. Ramos R, Comas-Cufí M, Martí-Lluch R, Balló E, Ponjoan A, Alves-Cabratosa L, et al. Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study. bmj. 2018;362. [DOI:10.1136/bmj.k3359]
21. Greabu M, Badoiu SC, Stanescu-Spinu II, Miricescu D, Totan AR, Badoiu SE, et al. Drugs interfering with insulin resistance and their influence on the associated hypermetabolic state in severe burns: a narrative review. International Journal of Molecular Sciences. 2021;22(18):9782. [DOI:10.3390/ijms22189782]
22. Andreana I, Bincoletto V, Milla P, Dosio F, Stella B, Arpicco S. Nanotechnological approaches for pentamidine delivery. Drug Delivery and Translational Research. 2022 :1-7. [DOI:10.1007/s13346-022-01127-4]
23. Iwata Y, Matsuhashi N, Takahashi T, Suetsugu T, Fukada M, Yasufuku I, et al. Diabetic ketoacidosis caused by fulminant type 1 diabetes during adjuvant chemotherapy for colon cancer: A case report. Molecular and Clinical Oncology. 2019;11(2):189-91. [DOI:10.3892/mco.2019.1862]
24. Cernea S, Dima L, Correll CU, Manu P. Pharmacological management of glucose dysregulation in patients treated with second-generation antipsychotics. Drugs. 2020 ;80(17):1763-81. [DOI:10.1007/s40265-020-01393-x]
25. Gupta D, Lee Chuy K, Yang JC, Bates M, Lombardo M, Steingart RM. Cardiovascular and metabolic effects of androgen-deprivation therapy for prostate cancer. Journal of oncology practice. 2018;14(10):580-7. [DOI:10.1200/JOP.18.00178]
26. Wang D, Eisen HJ. Mechanistic Target of Rapamycin (mTOR) Inhibitors. SpringerLink. 2022;272:53-2. [DOI:10.1007/164_2021_553]
27. Godswill AC, Godspel AC. Physiological effects of plastic wastes on the endocrine system (Bisphenol A, Phthalates, Bisphenol S, PBDEs, TBBPA). International Journal of Bioinformatics and Computational Biology. 2019;4(2):11-29.
28. Karaoglan M, Eksi F. The coincidence of newly diagnosed type 1 diabetes mellitus with IgM antibody positivity to enteroviruses and respiratory tract viruses. Journal of Diabetes Research. 2018;2018. [DOI:10.1155/2018/8475341]
29. Blum SI, Tse HM. Innate Viral Sensor MDA5 and coxsackievirus interplay in type 1 diabetes development. Microorganisms. 2020;8(7):993. [DOI:10.3390/microorganisms8070993]
30. Abu-Farha M, Al-Mulla F, Thanaraj TA, Kavalakatt S, Ali H, Abdul Ghani M, et al. Impact of diabetes in patients diagnosed with COVID-19. Frontiers in immunology. 2020;11:576818. [DOI:10.3389/fimmu.2020.576818]
31. Çiçek SS. Momordica charantia L. Diabetes-Related Bioactivities, Quality Control, and Safety Considerations. Frontiers in Pharmacology. 2022:1801. [DOI:10.3389/fphar.2022.904643]
32. Gray A, Threlkeld RJ. Nutritional recommendations for individuals with diabetes. http://www.ncbi.nlm.nih.gov/books/NBK279012/
33. Ko GJ, Obi Y, Tortoricci AR, Kalantar-Zadeh K. Dietary protein intake and chronic kidney disease. Current opinion in clinical nutrition and metabolic care. 2017;20(1):77. [DOI:10.1097/MCO.0000000000000342]
34. Kirwan JP, Sacks J, Nieuwoudt S. The essential role of exercise in the management of type 2 diabetes. Cleveland Clinic journal of medicine. 2017;84(7 Suppl 1):S15. [DOI:10.3949/ccjm.84.s1.03]
35. Vidanage D, Prathapan S, Hettiarachchi P, Wasalathanthri S. Impact of aerobic exercises on taste perception for sucrose in patients with type 2 diabetes mellitus; A randomized controlled trial. BMC Endocrine Disorders. 2022;22(1):1-2. [DOI:10.1186/s12902-022-00936-5]
36. Gowri MM, Rajendran J, Srinivasan AR, Bhavanani AB, Meena R. Impact of an Integrated Yoga Therapy Protocol on Insulin Resistance and Glycemic Control in Patients with Type 2 Diabetes Mellitus. Rambam Maimonides Medical Journal. 2022;13(1). [DOI:10.5041/RMMJ.10462]
37. Lin Y, Zhou S, Liu H, Cui Z, Hou F, Feng S, et al. Risk analysis of air pollution and meteorological factors affecting the incidence of diabetes in the elderly population in Northern China. Journal of diabetes research. 2020;2020. [DOI:10.1155/2020/3673980]
38. Zhang X, Yang S, Chen J, Su Z. Unraveling the regulation of hepatic gluconeogenesis. Frontiers in endocrinology. 2019;9:802. [DOI:10.3389/fendo.2018.00802]
39. Wood S, Magliano DJ, Bell JS, Shaw JE, Ilomäki J. Treatment Dynamics in People Who Initiate Metformin or Sulfonylureas for Type 2 Diabetes: A National Cohort Study. Frontiers in pharmacology. 2021:3526. [DOI:10.3389/fphar.2021.794273]
40. Ding QY, Tian JX, Li M, Lian FM, Zhao LH, Wei XX, et al. Interactions between therapeutics for metabolic disease, cardiovascular risk factors, and gut microbiota. Frontiers in Cellular and Infection Microbiology. 2020;10:530160. [DOI:10.3389/fcimb.2020.530160]
41. Dąbrowski M. Diabetes, antidiabetic medications and cancer risk in type 2 diabetes: focus on SGLT-2 inhibitors. International Journal of Molecular Sciences. 2021;22(4):1680. [DOI:10.3390/ijms22041680]
42. Silver B, Ramaiya K, Andrew SB, Fredrick O, Bajaj S, Kalra S, et al. EADSG guidelines: insulin therapy in diabetes. Diabetes therapy. 2018 Apr;9(2):449-92. [DOI:10.1007/s13300-018-0384-6]

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Iranian Journal of Diabetes and Obesity

Designed & Developed by : Yektaweb